TENX - Tenax Therapeutics Inc Stock Price, Fair Value and News

$5.61+0.05 (+0.90%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TENX Price Action

Last 7 days

-4.6%

Last 30 days

17.6%

Last 90 days

57.1%

Trailing 12 Months

-76.2%

TENX RSI Chart

TENX Valuation

Market Cap

19.1M

Price/Earnings (Trailing)

8.23

Price/Sales (Trailing)

1.17

Price/Free Cashflow

-2.74

TENX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TENX Fundamentals

TENX Revenue

Revenue (TTM)

13.9M

TENX Earnings

Earnings (TTM)

2.3M

Earnings Growth (Yr)

100.84%

Earnings Growth (Qtr)

210.76%

TENX Profitability

Return on Equity

2.39%

Return on Assets

2.33%

Free Cashflow Yield

-36.45%

TENX Investor Care

Buy Backs (1Y)

85.71%

TENX Alerts

JANUS HENDERSON GROUP PLC reported owning 10% of TENX [2024-11-14]

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	7.0M	9.3M	11.6M	13.9M
2015	0	49.3K	4.7M	0
2014	444.9K	263.0K	0	0
2013	1.1M	1.2M	1.1M	625.5K
2012	346.3K	381.1K	593.7K	1.0M
2011	0	104.1K	156.6K	224.7K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Tenax Therapeutics Inc

Tenax Therapeutics, Inc. develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension. It develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is based in Chapel Hill, North Carolina.

CEO	Mr. Christopher T. Giordano
WEBSITE	tenaxthera.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	7

Tenax Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Tenax Therapeutics Inc? What does TENX stand for in stocks?

TENX is the stock ticker symbol of Tenax Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tenax Therapeutics Inc (TENX)?

As of Fri Dec 20 2024, market cap of Tenax Therapeutics Inc is 19.12 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TENX stock?

You can check TENX's fair value in chart for subscribers.

Is Tenax Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether TENX is over valued or under valued. Whether Tenax Therapeutics Inc is cheap or expensive depends on the assumptions which impact Tenax Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TENX.

What is Tenax Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, TENX's PE ratio (Price to Earnings) is 8.23 and Price to Sales (PS) ratio is 1.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TENX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Tenax Therapeutics Inc's stock?

In the past 10 years, Tenax Therapeutics Inc has provided -0.632 (multiply by 100 for percentage) rate of return.